VIA
ENGN icon

Virtus Investment Advisers’s enGene Therapeutics ENGN Stock Holding History

Virtus Investment Advisers’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-31,445
Closed -$284K – 467
2025
Q4 		$284K Buy
+31,445
New +$252K 0.08% 264

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Virtus Investment Advisers's ENGN Position: Q1 2026 in Review

Virtus Investment Advisers sold out of enGene Therapeutics (ENGN) in Q1 2026, closing a stake of 31,445 shares — an estimated $284K sold.

Virtus Investment Advisers first reported a position in ENGN in Q4 2025 and held it in 1 quarter. The position peaked at $284K in Q4 2025. 61 funds tracked by Wall St. Rank hold ENGN as of Q1 2026.

  • Virtus Investment Advisers reported no remaining enGene Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Virtus Investment Advisers sold 31,445 enGene Therapeutics shares in Q1 2026, an estimated $284K.
  • Virtus Investment Advisers first reported a position in enGene Therapeutics in Q4 2025 and held it in 1 quarter.
  • Virtus Investment Advisers's enGene Therapeutics position peaked at $284K in Q4 2025.
  • 61 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2026.

Based on Virtus Investment Advisers's 13F filing for Q1 2026, filed 14 May 2026.